Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trialDavid Cunningham, Ruth E. Langley, Fareeda Y. Coxon et al.|The Lancet Oncology|2017Cited by 286
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trialsAlicia Okines, Andrew Wotherspoon, Srinivasan Madhusudan et al.|European Journal of Cancer|2013Cited by 40